Sofgen Pharma S.A.
Sofgen Pharma S.A. Fundamental Analysis
Sofgen Pharma S.A. (PROCF) shows weak financial fundamentals with a PE ratio of 0.00, profit margin of 9.52%, and ROE of -2.24%. The company generates $9.7B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -265.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze PROCF's fundamental strength across five key dimensions:
Efficiency Score
WeakPROCF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentPROCF trades at attractive valuation levels.
Growth Score
ModeratePROCF shows steady but slowing expansion.
Financial Health Score
WeakPROCF carries high financial risk with limited liquidity.
Profitability Score
WeakPROCF struggles to sustain strong margins.
Key Financial Metrics
Is PROCF Expensive or Cheap?
P/E Ratio
PROCF trades at 0.00 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, PROCF's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Sofgen Pharma S.A. at 0.05 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -2.68 times EBITDA. This is generally considered low.
How Well Does PROCF Make Money?
Net Profit Margin
For every $100 in sales, Sofgen Pharma S.A. keeps $9.52 as profit after all expenses.
Operating Margin
Core operations generate 17.01 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-2.24 in profit for every $100 of shareholder equity.
ROA
Sofgen Pharma S.A. generates $8.54 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Sofgen Pharma S.A. generates strong operating cash flow of $2.45B, reflecting robust business health.
Free Cash Flow
Sofgen Pharma S.A. generates strong free cash flow of $1.71B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.74 in free cash annually.
FCF Yield
PROCF converts 341.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
0.00
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.05
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.001
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1426.20
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.69
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-2.24
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
1.02
vs 25 benchmark
How PROCF Stacks Against Its Sector Peers
| Metric | PROCF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 0.00 | 29.78 | Better (Cheaper) |
| ROE | -224.21% | 792.00% | Weak |
| Net Margin | 9.52% | -23280.00% (disorted) | Weak |
| Debt/Equity | 1426.20 | 0.25 | Weak (High Leverage) |
| Current Ratio | 0.69 | 4.60 | Weak Liquidity |
| ROA | 8.54% | -18077.00% (disorted) | Weak |
PROCF outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Sofgen Pharma S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation